SciSparc shares surge 20.34% premarket as NeuroThera Labs signs non-binding term sheet to acquire 55% stake.

SciSparc surged 20.34% in premarket trading following the announcement that Neurothera Labs signed a non-binding term sheet to acquire a 55% stake in SciSparc Ltd., a quantum computing bio data company. The deal, though not yet finalized, signals strong investor confidence in the firm’s strategic value and potential collaboration opportunities. Elevated media sentiment scores and above-average news coverage in the past week further amplified market attention, contributing to the sharp premarket rally. The transaction aligns with the stock’s upward trajectory, driven by perceived upside from the proposed partnership.